Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical TrialMILAN, Italy and NEW YORK, Feb. 08, 2024 -- Genenta Science , a clinical-stage immuno-oncology company...

Related Keywords

Milan ,Lombardia ,Italy ,Tiziana Pollio ,Carlo Russo ,Luigi Naldini ,Pierluigi Paracchi ,Exchange Commission ,Head Of Development ,Telethon Institute For Gene Therapy ,Preliminary Data ,Ongoing Dose Ranging Stage ,Overall Survival ,San Raffaele ,Gene Therapy ,Tumor Microenvironment ,Glioblastoma Multiforme ,Securities Litigation Reform Act ,Annual Report ,Markets ,